# A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

> **NCT02717624** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Acerta Pharma BV** · enrollment: 72 (actual)

## Conditions studied

- Mantle Cell Lymphoma (MCL)

## Interventions

- **DRUG:** Acalabrutinib in combination with BR
- **DRUG:** Acalabrutinib in combination with VR

## Key facts

- **NCT ID:** NCT02717624
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-04-20
- **Primary completion:** 2022-06-15
- **Final completion:** 2027-08-20
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02717624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02717624, "A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02717624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*